Viking Therapeutics is a clinical-stage biotech with no revenue, entirely dependent on the success of its obesity drug VK2735. R&D spending surged 380% from $24.1M in 2024Q1 to $115.8M in 2026Q2, driving net losses to -$128.0M in 2026Q2. Cash reserves of $125....
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | -$1.10+10.6% vs -$1.23 | — vs — |
Q2 2026 Apr 29, 2026 | -$1.37-35.6% vs -$1.01 | — vs — |
Q1 2026 Feb 11, 2026 | -$1.38-55.1% vs -$0.89 | — vs $2M |
Q4 2025 Oct 22, 2025 | -$0.81-15.7% vs -$0.70 | — vs — |
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes Transcript
The Nasdaq 100 carved out a fresh intraday record by midday Tuesday as the artificial intelligence trade powered ahead.
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals
Viking Therapeutics (NASDAQ:VKTX), the clinical-stage biopharmaceutical company, surged over 27% in Tuesday morning trade after reporting trial data showing its obesity drug VK2735 maintained most patients' initial weight loss with less frequent dosing. The drug, a dual agonist targeting the GLP-1 and GIP receptors involved in appetite regulation, demonstrated weight loss maintenance after patients switched to less frequent dosing.
Benchmark VKTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Viking Therapeutics, Inc. (VKTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.85 | $4.77B | -12.81 | — | — | -47.34% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — | |
| $2.98 | $206.12M | -1.41 | — | — | -51.01% | — | |
| $122.06 | $10.04B | -33.08 | -16.72% | -285.41% | -21.5% | — | |
| $36.91 | $2.12B | -15.38 | — | — | -16.91% | — | |
| $77.74 | $6.86B | -37.38 | 254.7% | -3602.68% | -25.2% | — |
Viking Therapeutics, Inc. (VKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Viking Therapeutics, Inc. (VKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 26, 2026·SEC
Apr 29, 2026·SEC
Get notified when VKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Viking Therapeutics, Inc. (VKTX) stock FAQ — growth, dividends, profitability & financials explained
Viking Therapeutics, Inc. (VKTX) reported a net loss of $534.8M for fiscal year 2025.
Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -47.3%. Negative ROE indicates the company is unprofitable.
Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $418.4M in fiscal year 2025, likely due to heavy capital investments.
